What is the recommended antibiotic regimen and management for a urinary tract infection caused by Enterococcus faecalis, including options for uncomplicated cystitis and more severe infections in patients with urinary catheters or recent hospitalization?

Treatment of Urinary Tract Infection Caused by Enterococcus faecalis

For uncomplicated cystitis caused by E. faecalis, amoxicillin or ampicillin is the drug of choice, while nitrofurantoin and fosfomycin are excellent oral alternatives with FDA approval and high susceptibility rates. 1, 2

Uncomplicated Cystitis (Lower UTI)

First-Line Oral Options

• Amoxicillin 500 mg every 8 hours for 7 days is the preferred treatment for ampicillin-susceptible E. faecalis UTI 1, 2
• Amoxicillin is FDA-approved specifically for genitourinary tract infections due to susceptible (β-lactamase-negative) E. faecalis 2
• Nitrofurantoin demonstrates 96.7%-98.9% susceptibility against enterococci and is an excellent first-line option for uncomplicated cystitis 3
• Fosfomycin is FDA-approved for UTI caused by E. faecalis with 95.3%-100% susceptibility rates, though a 7-year surveillance study showed some declining activity 1, 3

Important Considerations for Lower UTI

• E. faecalis has only 2% vancomycin resistance compared to 60% for E. faecium, making it generally easier to treat 1
• Treatment duration should be 7 days for uncomplicated cystitis 1
• Nitrofurantoin may increase virulence properties of E. faecalis in some cases, though clinical significance in acute treatment remains unclear 4

Complicated UTI and Pyelonephritis

Parenteral First-Line Options

• Ampicillin 2 grams IV every 4-6 hours (or high-dose 18-30 grams IV daily) is the drug of choice for ampicillin-susceptible E. faecalis 1
• High urinary concentrations of ampicillin can overcome even ampicillin-resistant E. faecalis in UTI, with clinical and microbiological eradication rates of 88.1% and 86% respectively 1
• Vancomycin should be used if the organism is ampicillin-resistant 1

Combination Therapy Considerations

• Ampicillin plus gentamicin is more effective than monotherapy when urinary catheters are retained 1
• Combination therapy is not superior to monotherapy for uncomplicated infections when catheters are removed 1
• The combination shows synergistic activity and should be considered for catheter salvage attempts 1

Treatment Duration for Complicated UTI

• 7-14 days is the recommended duration, with 7 days appropriate for hemodynamically stable patients afebrile for ≥48 hours 1
• 14 days should be used for male patients, persistent complicating factors, or when using less bioavailable oral agents 5
• Treatment should continue for at least 48-72 hours beyond symptom resolution 2

Catheter-Associated UTI

Catheter Management

• Remove short-term catheters in all cases of confirmed E. faecalis UTI 1
• Long-term catheters can be retained with systemic antibiotic therapy for 7-14 days if no complications present 1
• Remove long-term catheters if insertion site infection, suppurative thrombophlebitis, sepsis, endocarditis, persistent bacteremia >72 hours, or metastatic infection occurs 1

Antibiotic Lock Therapy

• Should be used in addition to systemic therapy if long-term catheters are retained 1
• Combination of ampicillin plus gentamicin with antibiotic lock therapy is recommended for catheter salvage 1
• Success rates for antibiotic lock therapy alone are low and should not be used as monotherapy 1

Vancomycin-Resistant E. faecalis (VRE)

Treatment Options for VRE UTI

• Ampicillin remains the drug of choice even for ampicillin-resistant VRE in UTI due to high urinary concentrations achieving bactericidal activity 1
• High-dose ampicillin (18-30 g IV daily) or amoxicillin (500 mg every 8 hours) achieves sufficient urinary concentrations 1
• Linezolid or daptomycin should be used for ampicillin- and vancomycin-resistant strains based on susceptibility results 1
• Daptomycin at 8-12 mg/kg is preferred for serious VRE infections due to bactericidal activity 1

Alternative Oral Options for VRE Cystitis

• Nitrofurantoin has good in vitro activity against VRE with clinical data showing promising results for uncomplicated UTI 1, 6
• Fosfomycin demonstrates synergistic or additive effects when combined with linezolid, tigecycline, or gentamicin against VRE 1, 6
• These agents should be reserved for lower UTI only, not pyelonephritis or complicated infections 6

Critical Management Principles

Differentiate Colonization from Infection

• It is essential to differentiate colonization from true infection before prescribing anti-enterococcal therapy 1
• Asymptomatic bacteriuria with E. faecalis does not require treatment in most cases 7, 6
• Treatment is indicated only with urinary symptoms (dysuria, frequency, urgency) or systemic signs (fever, flank pain) 7, 6

Endocarditis Risk Assessment

• The risk of endocarditis with E. faecalis CRBSI is relatively low (1.5% in one multicenter study) but higher than with E. faecium 1
• Transesophageal echocardiography (TEE) should be performed if: new murmur, embolic phenomena, persistent bacteremia >72 hours despite appropriate therapy, prosthetic valve present, or septic pulmonary emboli 1
• Persistent bacteremia >4 days is independently associated with mortality and warrants TEE evaluation 1

Transition to Oral Therapy

• Switch to oral therapy when hemodynamically stable and afebrile for ≥48 hours 5
• Use susceptibility results to guide oral agent selection 5
• Oral options include amoxicillin, nitrofurantoin, or fosfomycin based on susceptibility 1, 2, 6

Common Pitfalls to Avoid

Antibiotic Selection Errors

• Do not use fluoroquinolones for enterococcal UTI—enterococci have intrinsic resistance mechanisms and fluoroquinolones are not reliable 7, 6
• Avoid cephalosporins as they have poor activity against enterococci 1
• Do not use tigecycline for UTI as it achieves inadequate urinary concentrations despite in vitro activity 1

Duration and Monitoring Errors

• Do not treat for only 5 days—this duration is validated only for uncomplicated pyelonephritis, not enterococcal UTI 5
• Obtain follow-up blood cultures if long-term catheters are retained to ensure clearance 1
• Do not discontinue therapy prematurely—continue for minimum 48-72 hours after symptom resolution 2

Catheter Management Errors

• Do not attempt catheter salvage in the presence of sepsis, persistent bacteremia, or metastatic infection 1
• Remove catheters whenever possible rather than relying on antibiotic lock therapy alone 1, 7

Special Populations

Hospitalized Patients with Recent Antibiotic Exposure

• 51.8% of patients with enterococcal UTI have recent antibiotic use within 3 months 8
• 59.3% have urinary catheters in place 8
• These patients require broader initial coverage and consideration of resistance patterns 8
• E. faecium infections in this population show higher mortality (23% vs 10.1%) and longer hospital stays compared to E. faecalis 8

Pediatric Patients on Prophylaxis

• Enterococci are isolated from almost half of pediatric patients on antibiotic prophylaxis for recurrent UTI 4
• Nitrofurantoin prophylaxis may increase enterococcal virulence properties 4
• Antibiotic prophylaxis may not be suitable for enterococcal recurrent UTI 4